Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
To characterise the development of adverse drug reactions (ADRs) of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Unresectable or recurrent BRCA mutated HER2 negative breast cancer with prior anticancer chemotherapy
You may not be if
The patients who are not started on Lymparza for the first time
Clareo Health | Lynparza Breast Cancer Clinical Experience Investigation
